Mangalam Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹79 crore and a net loss of ₹7.21 crore for the September 2026 quarter.
Mangalam Drugs (NSE: MANGALAM) closed at ₹27.55 on 20 Nov 2026. Its market capitalisation is ₹44 crore.
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.